TIME examines lawsuit against U.N. alleging responsibility for cholera outbreak

June 21, 2017

"Interestingly, some resistant patients had normal cereblon levels, suggesting that while cereblon may be an absolute requirement for response, there are likely other mechanisms present that play a role in drug resistance," said senior study author Keith Stewart, MD, Professor of Medicine in the Division of Hematology-Oncology and Dean of Research at Mayo Clinic in Scottsdale, Arizona. "These findings help us understand which patients may be more or less likely to respond to therapy and allow us to focus on other ways we can target cereblon as a possible biomarker to improve treatment and patient outcomes in multiple myeloma. This work also suggests that we can begin to dissect out the cause of birth defects from the anti-cancer properties and develop safer drugs in the future."

Source: Mayo Clinic

©2017 -